NEJM: Crizotinib Effective in Phase 1 Trial Against ROS1 Lung Cancer
September 30, 2014 · Comments Off
The New England Journal of Medicine reports positive results of a phase 1 clinical trial of the drug crizotinib against the subset of lung cancer marked by rearrangement of the gene ROS1.
A physician’s trip through the disease looking glass
June 2, 2014 · Comments Off
Let me tell you about the very rich. They are different from you and me,”...
Tumor Responses with Crizotinib in MET-Amplified Disease Help Define a New Targetable Form of Lung Cancer
June 2, 2014 · Comments Off
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
“Weeding the garden” with radiation allows ALK+ lung cancer patients to continue crizotinib, increasing survival
January 28, 2014 · Comments Off
CU Cancer Center study shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease. Eliminating these pockets of resistant disease allows patients to continue treating the overall condition with crizotinib, leading to improved 2-year survival rate compared with patients forced to discontinue the drug sooner.
Study finds known lung cancer oncogenes ALK and ROS1 also drive colorectal cancer
December 17, 2013 · Comments Off
Study shows that shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.
New Crizotinib Side-Effect: Reduced Measures of Kidney Function During Treatment (Recovery After)
November 20, 2013 · Comments Off
A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one of the most commonly used clinical methods.
Study: Redefining the criteria for ALK positive lung cancer
September 10, 2013 · Comments Off
A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug.
With early and obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
August 8, 2013 · Comments Off
When a drug's benefit is obvious in a clinical trial's first or second phase, is the third, costly phase needed? The question is posed in a recent edition of the journal Nature Reviews: Clinical Oncology by Robert C. Doebele, MD, PhD, investigator at the University of Colorado Cancer Center and assistant professor of medical oncology at the CU School of Medicine.
Reality TV meets reality for lung cancer treatment
June 6, 2013 · Comments Off
By Todd Neff It was Memorial Day Weekend 2012, and Ross Camidge, MD, PhD, was...
New Program Connects Patients and Survivors at CU Cancer Center
January 26, 2015 · No comments
amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer clinical trials cancer grants cancer prevention cancer research colorado Cancer Survivorship clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith